MicroRNA regulation of RAD51 in serous ovarian cancer modulates chemotherapy response

J Natl Cancer Inst. 2015 May 20;107(7):djv161. doi: 10.1093/jnci/djv161. Print 2015 Jul.

Authors

Erik A C Wiemer¹, Els M J J Berns²

Affiliations

¹ Dept. of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands e.wiemer@erasmusmc.nl.
² Dept. of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

PMID: 25995443
DOI: 10.1093/jnci/djv161

No abstract available

Publication types

Editorial
Comment

MeSH terms

Animals
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Biomarkers, Tumor / metabolism*
Cystadenocarcinoma, Serous / drug therapy*
DNA Damage / drug effects*
DNA, Neoplasm / drug effects*
Female
Humans
MicroRNAs / pharmacology*
Ovarian Neoplasms / drug therapy*
Rad51 Recombinase / metabolism*

Substances

Biomarkers, Tumor
DNA, Neoplasm
MicroRNAs
Rad51 Recombinase